Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Peter Valent, Joseph R. Carver et al.|European Heart Journal|2021Cited by 589
Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathySharie B. Parks, Ray E. Hershberger, Jessica D. Kushner et al.|American Heart Journal|2008Cited by 256
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic EffectsJoerg Herrmann, Joshua D. Mitchell, Ana Barac et al.|JAMA Oncology|2025Cited by 10